TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M

TELA Bio, Inc.

Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).
Q4 net loss $8.6M vs $7.8M; FY net loss $33.3M vs $28.8M.
Gross margin improved to 68% in Q4; full-year 64%.
Cash $43.9M at Dec 31, 2021.
FY2022 revenue guidance $40-$45M; preliminary Q1 2022 revenue ~$8.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.